data as a probe in antiviral drug discovery. Examples of both inosine 5' monophosphate and NAD + site-directed inhibitors are presented. Correlation of antiviral activities with IMPDH inhibition is discussed.
Viruses are the aetiological agents for some serious human infectious diseases. Although the discovery and development of vaccines and drugs have been successful in some antiviral therapeutic approaches, effective therapies are still not available for many existing and emerging viruses. This is particularly the case for many RNA viruses that exist worldwide and are the causative agents for a number of serious diseases.
The enzyme inosine monophosphate dehydrogenase (IMPDH, EC 1.1.1.205) has received considerable interest as an important target enzyme, not only for the discovery of anticancer drugs, but also in antiviral, antiparasitic and immunosuppressive chemotherapy (Nair, 2005; Franchetti et al., 1996; Ratcliffe, 2006) . IMPDH is a key enzyme in the biosynthesis of purine nucleotides. It catalyses the NAD + -dependent oxidation of inosine 5′-monophosphate (IMP) to xanthosine 5′-monophosphate (XMP). This is a rate-limiting step in the de novo synthesis of guanine nucleotides (Figure 1) (Nair, 2005; Pankiewicz and Goldstein, 2003) . The enzymatic reaction can be examined by UV spectroscopy through monitoring the formation of NADH at 340 nm.
Inhibition of IMPDH causes an overall reduction in guanylate pools and, as GTP is a cofactor in the conversion of IMP to AMP, adenylate pools are also depleted. Subsequent interruption of DNA and RNA synthesis results in cytotoxicity (Balzarini et al., 1993; Balzarini et al., 1998) .
Some support for using the correlation of IMPDH inhibition in approaches to drug discovery, particularly that focused on highly pathogenic RNA viruses, comes from a characteristic of many RNA viruses: a high frequency of mutation and the accompanying potential susceptibility to the phenomenon of error catastrophe (Holland et al., 1990; Lee et al., 1997; Crotty et al., 2000) . When mutations, including those resulting from inhibitor incorporation, reach a certain threshold value, the concomitant loss of genetic information will impair the ability of the virus to properly replicate. It has been suggested that animal RNA viruses maintain themselves on the borderline of error catastrophe (Holland et al., 1990) .
Mechanism of the substrate activity of IMPDH
The mechanism of the biochemical conversion of IMP to XMP catalysed by IMPDH is initiated by nucleophilic attack of the active-site residue, Cys331 (numbering in human IMPDH), on IMP to form a covalent bond between the 2-position of IMP and the sulfhydryl group of Cys331 (Kerr and Hedstrom, 1997; Link and Straub, 1996) . A hydride ion is then transferred to the cofactor, NAD + , to produce NADH and the intermediate E-XMP*. Subsequently E-XMP* is subject to hydrolysis, which liberates XMP via a tetrahedral intermediate E-XMP † (Figure 2) .
Human IMPDH has two isoforms, type I and type II, and each is a tetramer consisting of 56 kDa monomers. They have 84% sequence identity and exhibit kinetic properties that are similar. Type I IMPDH appears to be prevalent in normal human leukocytes and lymphocytes Nagai et al., 1992) , while the type II enzyme predominates in tumour and rapidly proliferating cells Nagai et al., 1992) . However, they are both likely to contribute to the proliferative responses of lymphocytes (Dayton et al., 1994) . Inhibition of the type I enzyme is sufficient to cause endothelial cell cycle arrest (Chong et al., 2006) . It has been suggested as an antiangiogenic drug target. Mutations in the type I gene cause the RP10 form of autosomal dominant retinitis pigmentosa (Bowne et al., 2002) . In mice, loss of both alleles of the type II gene results in very early embryonic lethality. Type I enzymatic activity is not essential for normal mouse development or fertility (Gu et al., 2003) . Significant advances in the understanding of IMPDH have been provided by crystallographic studies. Several crystal structures of IMPDH have been reported and are useful in drug design and in drug discovery. An example of the ribbon diagram of a human type II IMPDH crystallographic structure is shown in Figure 3 (Colby et al., 1999) .
Inhibitors of IMPDH
According to the binding position and the competitive relationship with IMP and NAD + , IMPDH inhibitors have been divided into three categories. One is a ligand that occupies the binding position of the natural substrate, IMP. The other is a ligand that occupies the site of the cofactor, NAD + /NADH. A third is a ligand that binds to a site remote from the IMP and NAD + pockets and is referred to as an allosteric site inhibitor. All mechanisms of inhibition could interfere or even terminate the substrate activity process by blocking or by altering the conformation in IMP and NAD + sites.
IMP site inhibitors
Some nucleosides (Figure 4 ), as their monophosphates (MPs), can inhibit IMPDH by competing with IMP for binding with IMPDH. Examples include ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; Hager et al., 1995) , mizoribine (4-carbamoyl-1-β-D-ribofuranosyl-imidazolium-5-olate; Hager et al., 1995) , EICAR Minakawa et al., 1991; Matsuda et al., 1988) , 6-chloropurine riboside (Brox & Hampton, 1968; Antonino et al., 1994) , 3-deazaguanosine (Cook et al., 1976; Streeter & Koyama, 1976 ) and 2-vinylinosines (Pal et al., 2002; Nair and Kamboj, 2003) .
Experimental data (Nair & Kamboj, 2003; Wang et al., 1996) suggest that EICARMP and 2-vinylinosine MP irreversibly inactivate IMPDH. It is believed that the irreversible inhibition involves a Michael addition of the sulfhydryl group of Cys331 (human IMPDH numbering) at the unsaturated bond of the ligand, resulting in the formation of a covalent bond between the inhibitor and the enzyme.
The IMP binding site is relatively conserved among different species. Using human type II IMPDH as an example, each of its monomers consists of 514 amino acids. The IMP site is a cavity within the enzyme, which is defined by Ser68, Pro69, Met70, Asp71, Thr72, Val73, Thr74, Ser276, Gln277, Asn303, Val304, Arg322, Val323, Ser327, Gly328, Ser329, Ile330, Cys331, Ile332, Thr333, Gln334, Glu335, Val336, Asp364, Gly365, Gly366, Ile367, Gln368, Met385, Met386, Gly387, Ser388, Leu389, Leu390, Tyr412, and Arg413.
For 6-chloropurine nucleoside MP (6ClPurNMP), the X-ray crystallographic structures (Colby et al., 1999) of its complex with IMPDH shows that the 6-chloro-substituted purine base is dehalogenated and forms a covalent bond at C-6 with Cys331. The affinity between the inhibitor and IMPDH enzyme involves various polar interactions, which appear to be conserved across species. The phosphate group is locked into position by hydrogen bonding interactions with Ser329, Gly366, Gly387, Ser388 and the ribose hydroxyls form hydrogen bonds with Ser68 and Asp364. The hydroxyl group of the conserved Tyr411 interacts with N-7 of the base moiety of the inhibitor ( Figure 5 ).
NAD + site inhibitors
The NAD + binding site is less conserved among different species than the IMP binding site. Structural modification of NAD + has led to the discovery of some NAD + site inhibitors of IMPDH (Digits and Hedstrom, 2000; Pankiewicz and Goldstein, 2003) . NAD + site inhibitors include thiazole-4carboxamide adenine dinucleotide (TAD; Pankiewicz et al., 2004; Marquez et al., 1986; Gebeyehu et al., 1985) and its analogues, and mycophenolic acid (MPA; Figure 6 ) (Gan Cooney et al., 1982; Jayaram et al., 1983) . TAD is the cellularly active metabolite of tiazofurin (Cooney et al., 1982; Jayaram et al., 1983) . Its structure is related to NAD + . Enzymatic inhibition data suggest that it is a non-competitive inhibitor of IMPDH with respect to NAD + . Tiazofurin was found to have both antiproliferative and antiviral activities (De Clercq, 2001; Minakawa & Matsuda, 1999) .
Correlation of IMPDH inhibition with antiviral activity
Ribavirin Various mechanisms have been proposed for the antiviral activity of ribavirin (Graci & Cameron, 2006) . It includes inhibition of RNA capping activity, inhibition of viral polymerase, and introduction of mutagenic base pairing into the viral genome through incorporation, leading to error catastrophe. However, at least a part of this antiviral activity has been attributed to the inhibition of IMPDH by ribavirin 5′-monophosphate. Another mechanism suggests that, in the case of the poliovirus and perhaps other RNA viruses, ribavirin may have a lethal mutagenic effect following its incorporation (via its triphosphate) into the viral RNA genome. This process of incorporation is catalysed by the viral RNA-dependent RNA polymerase (Crotty et al., 2000; Lee et al., 1997) . Incorporation of this non-natural nucleotide into viral RNA forces the RNA virus into a lethal accumulation of errors. This is amplified further by the reduction of GTP pools caused by the inhibition of IMPDH by ribavirin monophosphate (Crotty et al., 2001) . Decrease in the cellular GTP pools is likely to increase the frequency of incorporation of ribavirin triphosphate because it acts as a GTP analogue.
It has also been suggested that inhibition of IMPDH is the predominant mechanism of the antiviral activity of ribavirin against flaviviruses and paramyxoviruses (Leyssen et al., 2005) . Three IMPDH inhibitors, ribavirin, EICAR and MPA, showed similar linear correlations between GTP pool inhibition and antiviral activity against viral RNA synthesis in four flaviviruses (dengue, yellow fever, Modoc virus and Montana myotis leukoencephalitis virus), and two paramyxoviruses (respiratory syncytial virus [RSV] and human parainfluenza virus 3). Guanosine reverses the inhibition.
Currently, ribavirin is approved by the FDA as an inhaled drug for treatment of RSV (Cooper et al., 2003) and, orally together with α-interferon, for the treatment of hepatitis C virus (HCV; Pawlotsky, 2003) . It is of interest that ribavirin produced positive responses when used in combination with interferon-α against chronic hepatitis C, when patients did not respond to interferon alone. Synergistic effects were also discovered when ribavirin was used in combination with other antiviral compounds. It was found that ribavirin could potentiate the anti-HBV activity of the entecavir against both wild-type HBV and the lamivudine-resistant virus (Ying et al., 2007) , and enhance the anti-HIV activity of 2′,3′-dideoxyinosine (Balzarini et al., 1991a) . Combined with PM-523 (a polyoxometalate), ribavirin is said to enhance, by 23%, the inhibitory activity of PM-523 against the influenza A virus (H1N1) in MDCK cells (Shigeta et al., 1997) .
EICAR
EICAR is a congener of ribavirin but appears to have higher potency. The activity includes both DNA and RNA viruses. Inhibitory activities (50% effective concentration [EC 50 ]) ranging from 0.2 to 4 μg/ml were found against poxviruses, togaviruses, arenaviruses, reoviruses, rhabdoviruses, orthomyxoviruses, and paramyxoviruses (De Clercq et al., 1991) . EICAR was particularly active against RSV in the paramyxovirus family. For the four strains of RSV A and B used in the experiment, EICAR showed good EC 50 data (0.06 to 0.13 μg/ml) (Shigeta et al., 1992) . EICAR has also been screened against Birnaviridae (pancreatic necrosis virus; Jashes et al., 2000) and Flaviviridae (yellow fever virus; Neyts et al., 1996) , with EC 50 s of 0.01 and 0.8 μg/ml, respectively. The mechanism of action of this compound appears to be manifold and might include inhibition of IMPDH through its 5′-MP, inhibition of IMPDH through an NAD + analogue (EICAR adenine dinucleotide), inhibition of viral RNA polymerase through EICAR triphosphate and inhibition of viral mRNA capping (Minakawa and Matsuda, 1999) . As in the case of ribavirin, the inhibitory activity of EICAR against IMPDH is suggested as the predominant mechanism against flaviviruses and paramyxoviruses (Leyssen et al., 2005; Leyssen et al., 2006) . Similar synergistic effects were found when EICAR was used in combination with 2′,3′-dideoxyinosine. The anti-HIV activity was increased up to fourfold in peripheral blood lymphocytes (Balzarini et al., 1991b) .
Mizoribine
Mizoribine, also known as bredinin, is one of the most potent inhibitors of IMPDH. Its active metabolite, mizoribine 5′-MP is thought to mimic the transition state of IMPDH catalysis (Kerr & Hedstrom, 1997) . Mizoribine exhibits broad-spectrum antiviral activity, including activity against three strains of RSV, one strain each of influenza A and B, parainfluenza virus types 2 and 3, mumps virus, and the measles virus (Kosugi et al., 1994) . EC 50 values in the submicromolar range were observed with some of these viruses. Mizoribine was between onefold and ninefold more active than ribavirin against these viruses. Mizoribine shows strong synergistic effect against the bovine viral diarrhoea virus in MDBK cells in combination with IFN-α (Yanagida et al., 2004) . The 10:1 combination of IFN-α and mizoribine gave an EC 50 of 0.66 μM, whereas mizoribine alone gave an EC 50 of 5.3 μM. This compound has also been suggested to be a new anti-HCV agent (Kato et al., 2006; Naka et al., 2005) . Mizoribine also shows activity against vaccinia virus (Mizuno et al., 1974) and human cytomegalovirus (HCMV; Shiraki et al., 1990) . The mechanism of viral inhibition appears to be associated with inhibition of IMPDH by the MP of this compound. Consistent with this is the observation that the antiviral activities of mizoribine against viruses can be reversed by guanosine and GMP (Kosugi et al., 1994) . Mizoribine has been approved in Japan for use in the prevention of organ allograft rejection, and in the treatment of rheumatoid arthritis, primary nephrosis, lupus nephritis, dermatomyositis and autoimmune dermatoses (Ishikawa, 1999) .
2-Substituted purine nucleosides
In the Nair laboratory, a series of 2-functionalized hypoxanthine and purine nucleosides (Figure 7) have been synthesized and their MPs have been examined for inhibition of Escherichia coli IMPDH Nair et al., 2005; Nair et al., 2007) . The values of k inact and K i were as follows: 2-ethynylinosine MP 0.012 s -1 and 4.3 μM; 6-chloro-2-ethynylpurine ribonucleoside MP 0.030 s -1 and 4.7 μM; 2-vinylinsoine MP 0.029 s -1 and 4.0 μM (Pal et al., 2002) ; 2-[2-(Z)-fluorovinyl]inosine MP 0.027 s -1 and 1.1 μM (Nair and Kamboj, 2003) . In vitro antiviral evaluations showed that 6-chloro-2-ethynylpurine ribonucleoside was inactive (IC 50 >0.80 μg/ml, CC 50 3.0 μg/ml) and so was 2-ethynylinosine (IC 50 >20 μg/ml, CC 50 66 μg/ml). 6-Chloro-2-(3-fluoropropynyl)purine riboside and 2-(3-fluoro-propynyl)inosine were also inactive. Both 2-(2-fluorovinyl)inosine and 6-chloro-2-(2fluorovinyl)purine riboside showed moderate activity towards the vaccinia virus in human foreskin fibroblasts. Interestingly, 2-vinylinosine shows broad-spectrum in vitro antiviral activity against a number of viruses (IC 50 in Vero cells except for adenovirus 2 [Ad2], which was in hep2 cells): vaccinia virus 13 μg/ml; Japanese encephalitis virus 2.0 μg/ml; arenavirus 2.5 μg/ml; phlebovirus 2.7 μg/ml; Rift Valley fever virus, 24 μg/ml); Venezuelan equine encephalomyelitis virus 7.7 μg/ml; yellow fever virus 7.7 μg/ml; and Ad2 13 μg/ml (Nair and Ussery, 1992) .
TAD, SAD and BAD
Tiazofurin and its selenium analogue, selenazofurin, were first synthesized by Robins and co-workers (Srivastava et al., 1977; Srivastava and Robins, 1983) . They are phosphorylated in cells to their MPs, which are the precursors of the active anabolites, tiazofurin adenine nucleotide TAD + and selenazofurin adenine nucleotide SAD + . A feature in their structures, which produces the active conformation of TAD + and SAD + , is the result of a constraint on the rotation of the C-glycosidic bond (Franchetti et al., 1996) . Tiazofurin and selenazofurin both show broad-spectrum antiviral activity against both DNA and RNA viruses (Robins et al., 1985) . Although the level of activity of selenazofurin against different viruses varied, it was significantly more potent than tiazofurin and ribavirin against all tested representatives of the families Paramyxoviridae, Reoviridae, Herpesviridae, Togaviridae, Bunyaviridae, Arenaviridae, Picornaviridae, Adenoviridae, and Rhabdoviridae. For the flavivirus family, selenazofurin inhibits the yellow fever virus and the Japanese encephalitis virus in Vero-76 cells with EC 50 values of 0.0050 and 3.0 μg/ml, respectively, whereas tiazofurin showed much lower activity with EC 50 values of 9.2 and 73 μg/ml, respectively (Kirsi et al., 1983) . The antiviral activities of tiazofurin and selenazofurin were readily reversed by exogenous guanosine (Robins et al., 1985) indicating that the antiviral potency was related to the inhibition of IMPDH.
IMPDH inhibitors have also been tested against the replication of phytoviruses to identify compounds with the ability to control plant viral diseases. Grapevine leafroll-associated virus 3 is one member of the genus Ampelovirus and it causes grapevine yield losses and reduction of berry sugar concentration. Tiazofurin was found to be capable of eradicating this virus to achieve a substantial rate of virus-free plants with treatments of 60 μg/ml for 30 days (Panattoni et al., 2007) .
Recently, benzamide riboside [3-(1-deoxy-β-D-ribofuranosyl)benzamide; Figure 6 ], has been shown to be a potent inhibitor of IMPDH (Szekeres et al., 2002) . As in the case of tiazofurin and selenazofurin, benzamide riboside is metabolized to benzamide adenine dinucleotide (BAD), which binds in the NAD + site. Benzamide riboside is more efficiently converted to its active metabolite than tiazofurin (Gharehbaghi et al., 1994) . It also exhibits slightly higher activity against human myelogenous leukemia K562 cells than tiazofurin (IC 50 2.5 μM versus 7.5 μM; Jayaram et al., 1992) . In addition, unlike tiazofurin, benzamide riboside can induce apoptosis in various human tumour cell lines (Szekeres et al., 2002) .
Non-nucleoside compounds
MPA (Figure 6 ), the active metabolite of mycophenolate mofetil (CellCept®, Roche, Basel, Switzerland), has been approved in the USA as an immunosuppressant for the prevention of acute rejection in kidney (Shaw et al., 1995) and heart transplants (Kobashigawa et al., 1998) . MPA is a uncompetitive inhibitor of IMPDH with respect to both IMP and NAD + (Fleming et al., 1996; Gan et al., 2002; Link and Straub, 1996) . It has been suggested that MPA binds to the enzyme after the ternary complex is formed between the enzyme, IMP and NAD + and impedes the hydrolytic attack at the C-2 position (Figure 2) .
MPA exhibits some species selectivity as an IMPDH inhibitor. Mammalian IMPDHs are very sensitive to MPA (K i 20 nM for human IMPDH), while microbial IMPDHs are much less so (K i 0.2 μM for Leishmania donovani, K i 9 μM for Trichomonas foetus and K i 20 μM for E. coli) (Digits and Hedstrom, 1999; Digits and Hedstrom, 2000) . between human and bacterial enzymes in the catalytic process ( Figure 2 ). According to the position of the flap, there are two conformations of E-XMP*. The human IMPDH prefers the open conformation whereas bacterial enzymes prefer the closed one, which is the conformation in which the hydrolysis reaction occurs (Hedstrom and Gan, 2006) . As in the cases of ribavirin and EICAR, inhibition of IMPDH by MPA was thought to be the predominant mechanism of the antiviral activity of MPA against flaviviruses and paramyxoviruses (Leyssen et al., 2005; Ichimura and Levy, 1995) . MPA has been tested against orthopoxviruses (Smee et al., 2001) . Camelpox, cowpox, monkeypox and vaccinia viruses were inhibited by 50% in plaque reduction assays at 0.2-3 μM (Vero-76 and mouse 3T3 cells). It was found that virus inhibition was closely correlated with the extent of suppression of intracellular GTP pools. MPA also shows activity against avian reoviruses (ARV). It was found that at a concentration of 3 μg/ml, MPA would completely inhibit the replication of ARV in QM5 quail fibrosarcoma in HD-11 and Vero cells (Robertson et al., 2004) . Recently, MPA has been identified to be active against the replication of Dengue viruses (DEN) . The values of EC 50 against DEN2 in monkey kidney (LLC-MK2) cells are of the order of 0.4 μM (Takhampunya et al., 2006) , which is about 125× more active than ribavirin. However, there is a significant overall problem with MPA and its therapeutic potential because it is easily converted to MPA-7-O-glucuronide (Franklin et al., 1995) , which limits its efficacy. Higher doses are therefore needed in order to maintain appropriate therapeutic levels.
To overcome the limitations of MPA, alternative non-phenolic analogue structures were sought (Figure 8 ). Using computer-based drug design and highthroughput screening, a series of phenyloxazole urea compounds were developed as IMPDH inhibitors by the Vertex group (Sintchak and Nimmesgern, 2000 ; Jain ©2007 International Medical Press et al., 2002) . Their compounds, VX-497 and VX-148, have high potency against IMPDH, which is similar to MPA. At present, both compounds are in clinic trials. VX-497 shows inhibitory activity against a wide variety of viruses including DNA and RNA viruses (Markland et al., 2000) . For example, the values of EC 50 against HBV, HCMV, RSV and murine encephalomyocarditis virus are 0.4, 0.8, 1.1 and 1.0 μM, respectively. VX-497 is consistently more potent than ribavirin against all viruses except the influenza A virus. The higher potency of VX-497 is linked directly to its higher affinity and inhibition of IMPDH (K i 10 nM for VX-497 versus 390 nM for ribavirin). The observation that guanosine can reverse the antiviral effects is indicative of the important contribution of IMPDH inhibition in the antiviral activity. In clinical trials, VX-497 is promising to replace ribavirin for the treatment of HCV infection in combination with interferon-α (McHutchison et al., 2005) . Other heterocyclic IMPDH inhibitors have also been synthesized as potential antiviral agents, including BMS-337197 (Dhar et al., 2002) , quinazolinethiones and quinazolinediones (Buckley et al., 2005) , and oxamides (Pickett et al., 2003) .
Conclusions
IMPDH, an important enzyme in the biosynthesis of purine nucleotides, has been suggested as a probe in the discovery of antiviral compounds, particularly those targeted against infectious RNA viruses. High activity of IMPDH exists in virus-infected cells, where significant amounts of nucleotide pool compounds are required for rapid viral proliferation. Thus, IMPDH inhibitors may exhibit some selectivity against virus-infected cells, as reduced substrate activity involving IMPDH, resulting in depletion of guanylate and adenylate pools, would have a greater effect on the replicating virus than the replicating normal cell. Also, a characteristic of many RNA viruses is a high frequency of mutation. When mutation, including that resulting from IMPDH inhibitor incorporation into the viral genome, reaches a certain threshold value, viral replication is impaired. Finally, because of limitations on both efficacy and selectivity, the antiviral therapeutic potential of IMPDH inhibitors can be dramatically increased through drug combination approaches.
